Medical Device Electronic Labeling Act

Bill Number

H.R. 1539

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-02-24: Referred to the House Committee on Energy and Commerce.

Last Updated

2026-03-25T08:05:37Z

AI-Generated Summary

Purpose

The Medical Device Electronic Labeling Act (H.R. 1539) aims to modernize the labeling requirements for medical devices under the Federal Food, Drug, and Cosmetic Act (FD&C Act). It expands the ability to provide required labeling—such as instructions for use and safety warnings—exclusively through electronic formats, while ensuring accessibility and safety for users.

Key Provisions

• Electronic Labeling Option: Manufacturers of medical devices, including in vitro diagnostic devices (tests performed on samples like blood outside the body), may provide required labeling solely via electronic means if it meets specific conditions.
• Accessibility Requirements:
• The electronic labeling must be easily accessible to the device's intended users (e.g., healthcare professionals or patients).
• Users must be given a free option to request a paper version, which the manufacturer must provide promptly upon request.
• The physical label on the device or its immediate container must still include all necessary information to comply with the FD&C Act and any related regulations or orders.
• FDA Oversight: The Secretary of Health and Human Services (who oversees the Food and Drug Administration, or FDA) may issue orders to add requirements or exceptions for electronic labeling on specific device types. These orders must be proposed and finalized through public notice in the Federal Register (a government publication for proposed rules) and consider public comments. Additional requirements can only be imposed if needed to ensure the device's safety and effectiveness.

Significant Changes to Existing Law

• Amends Section 502(f) of the FD&C Act, which previously required physical labeling with adequate directions for use and warnings against unsafe use (with exemptions only if not needed for public health).
• Expands electronic-only labeling beyond limited cases (e.g., previously allowed for some software-based devices) to a broader range of devices, including in vitro diagnostics, while maintaining core safety standards.
• Introduces a streamlined process for FDA orders on labeling, bypassing some standard rulemaking procedures under the Administrative Procedure Act (which governs how agencies create rules) to allow quicker adaptations.

Potential Impacts

• On Government Agencies: The FDA gains flexibility to regulate electronic labeling efficiently through targeted orders, potentially reducing administrative burdens but requiring resources for public comment reviews and enforcement.
• On Citizens: Healthcare providers and patients benefit from easier access to up-to-date digital information, but must have internet or electronic access; the paper request option protects those without digital means.
• On International Relations: Minimal direct impact, though it could align U.S. standards with global trends toward digital health documentation, potentially easing exports of U.S. medical devices.
• Overall, it promotes environmental benefits by reducing paper use and may lower costs for manufacturers, indirectly benefiting consumers through potentially lower device prices.

Main Stakeholders Affected

• Medical Device Manufacturers: Gain flexibility in labeling to cut costs and improve efficiency, but must ensure electronic access and handle paper requests.
• Healthcare Providers and Patients: Primary users who need clear access to labeling; electronic formats could speed up information retrieval, but accessibility safeguards prevent exclusion.
• FDA and Regulators: Responsible for overseeing compliance, issuing orders, and balancing innovation with safety.
• Environmental and Consumer Advocacy Groups: May support reduced paper waste but monitor for any risks to user safety or digital divides.

Notable Legal, Constitutional, or Political Implications

• Legal: Strengthens device safety by tying electronic labeling to FDA oversight and public input processes, ensuring compliance with due process (fair procedures) under the Administrative Procedure Act. It maintains the FD&C Act's focus on public health protection without altering core misbranding penalties.
• Constitutional: No direct challenges, as it expands regulatory flexibility within Congress's authority to regulate interstate commerce and public health under the Commerce Clause.
• Political: Bipartisan introduction (by representatives from both parties) suggests broad support for modernizing FDA rules amid growing digital health trends. It could influence future legislation on electronic records in healthcare, emphasizing innovation while addressing equity concerns like digital access.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Obernolte, Jay [R-CA-23]

Cosponsors (7)

Rep. Mullin, Kevin [D-CA-15], Rep. Crenshaw, Dan [R-TX-2], Rep. Craig, Angie [D-MN-2], Rep. Peters, Scott H. [D-CA-50], Rep. Miller-Meeks, Mariannette [R-IA-1], Rep. Bilirakis, Gus M. [R-FL-12], Rep. Gottheimer, Josh [D-NJ-5]

Recent Actions

• 2025-02-24: Referred to the House Committee on Energy and Commerce.
• 2025-02-24: Introduced in House
• 2025-02-24: Introduced in House

Bill Versions

• Medical Device Electronic Labeling Act — issued 2025-02-24 — PDF (3 pages)